AUS
NZ
UK
CA
USA
IND
Healthcare
Scancell Holdings Outlines Ambitious Roadmap for the Next 18 Months
September 24, 2024 10:49 AM BST| By Team Kalkine MediaScancell Holdings PLC,(LSE:SCLP),has outlined an ambitious roadmap for the next 18 months, capitalizing on the clinical advancements achieved so far in its cancer immunotherapy initiatives.,Upcoming Milestones,A key early milestone includes the antic...
Roquefort Therapeutics Secures Japanese Patent for MK Technology, Plans Expansion in Japan
September 23, 2024 12:17 PM BST| By Team Kalkine MediaRoquefort Therapeutics PLC,(LSE:ROQ),has achieved a significant milestone by securing a patent in Japan for its Mesodermal Killer (MK) cell therapy, a promising development in the fields of cancer and immune system treatments. This patent follows a s...
ANGLE Secures FDA Clearance for Parsortix, Set to Revolutionize Cancer Detection
September 23, 2024 11:34 AM BST| By Team Kalkine MediaANGLE PLC,(LSE:AGL),is a leader in the field of liquid biopsy, renowned for its cutting-edge sample-to-answer solutions. The company’s flagship technology, the Parsortix® system, is a patent-protected platform that allows for the harvesting of circul...
Roquefort Therapeutics reports siRNA success in immunology
September 19, 2024 09:52 AM BST| By Team Kalkine MediaRoquefort Therapeutics PLC (LSE:ROQ) recently announced that its STAT-6 siRNA has shown effectiveness in an in-vitro model of immunological disease. This development follows direct feedback from potential major pharmaceutical partners.,siRNA technolo...
ANGLE Collaborates with Recursion Pharmaceuticals on Study
September 19, 2024 08:12 AM BST| By Team Kalkine MediaANGLE PLC,(LSE:AGL),has announced a significant development by signing an agreement with Recursion Pharmaceuticals Inc., a Nasdaq-listed clinical-stage 'techbio' company. This collaboration involves a fully funded pilot study focused on experimental...
GSK Reaches Settlement in Two California Zantac Cases
September 18, 2024 04:07 PM BST| By Team Kalkine MediaOn Wednesday, GSK announced that it had reached confidential settlements in two lawsuits filed in California State Court concerning its discontinued heartburn medication, Zantac, also known as ranitidine. The pharmaceutical giant disclosed that these...
PZ Cussons (LSE:PZC) Announces Retirement of Senior Independent Director John Nicolson
September 18, 2024 10:33 AM BST| By Team Kalkine MediaPZ Cussons plc (LSE:PZC) has announced that John Nicolson, Non-Executive Director and Senior Independent Director, will retire and will not seek re-election at the Company’s Annual General Meeting (AGM) on 21 November 2024. Nicolson, who has served a...
Poolbeg Pharma Highlights POLB 001 Interest and Financial Discipline
September 18, 2024 09:24 AM BST| By Team Kalkine MediaPoolbeg Pharma PLC,(LSE:POLB),has outlined significant advancements for its lead drug, POLB 001, in its recent first-half results report, which also noted a cash balance of £10.1 million as of June 30.,POLB 001 is being developed as the first approve...
Advanced Medical Solutions (LSE:AMS) Delivers Revenue Growth in Latest Half Driven by Surgical Business Surge
September 18, 2024 09:21 AM BST| By Team Kalkine MediaAdvanced Medical Solutions Group plc (LSE:AMS), a global leader in tissue-healing technologies, has released its unaudited interim results for the six months ending 30 June 2024. The company reported an 8% increase in revenue, reaching £68.0 million,...
Synairgen Names Inhaled Drug Development Expert as Chairman
September 18, 2024 08:28 AM BST| By Team Kalkine MediaSynairgen PLC,(LSE:SNG),has announced that chairman Simon Shaw will retire at the upcoming annual shareholder meeting, set for 10 October in London. He will be succeeded by Mark Parry-Billings, recognized as a leader in inhaled drug development.,Dr....
MaxRets Ventures Appoints Non-Executive Director
September 17, 2024 08:52 AM BST| By Team Kalkine MediaMaxRets Ventures PLC,(LSE:MAX),has announced the appointment of Luca Zanni as a non-executive director. Zanni, aged 44, is recognized for his extensive experience in financial management across a variety of industries.,Zanni’s career includes a serie...
Panmure Says - Scancell Well-Positioned to Secure Funding
September 17, 2024 08:29 AM BST| By Team Kalkine MediaBroker Panmure Liberum has reiterated its favorable rating on Scancell Holdings PLC (LSE:SCLP) shares, maintaining a target price of 23.3p in light of Scancell’s recent strategic partnership with PharmaJet. The collaboration is set to utilize PharmaJ...
Scancell Partners with ParmaJet for Needle-Free Cancer Vaccine Delivery
September 17, 2024 08:18 AM BST| By Team Kalkine MediaScancell Holdings PLC,(LSE:SCLP),has entered into a strategic partnership with PharmaJet to provide the Stratis intramuscular (IM) needle-free injection system. This system will be utilized for administering Scancell’s SCIB1/iSCIB1+ DNA cancer vaccin...
Ananda Raises £2.2M Total, with Additional £80K from Retail Offer
September 16, 2024 09:04 AM BST| By Team Kalkine MediaAnanda Developments Plc (AQSE: ANA) has announced the successful raising of £2.225 million through a combination of financing efforts. The total amount includes £79,996 acquired via a WRAP retail offer, supplementing the proceeds from a recent placin...
AstraZeneca Drops After Downgrade Following Cancer Drug Update
September 13, 2024 06:40 PM BST| By Team Kalkine MediaAstraZeneca,(LSE:AZN),experienced a decline of £4 billion in its market value following a downgrade from Deutsche Bank, which has revised its recommendation for the company to 'sell' in light of the latest update on the lung cancer drug datopotamab.,...
Proteome Sciences Slips as Losses Mount and CEO Steps Down
September 13, 2024 06:32 PM BST| By Team Kalkine MediaProteome Sciences PLC,(LSE:PRM),experienced a significant drop of over 17% in its share value on the back of a recent announcement detailing increased financial losses and the resignation of its chief executive, Mariola Soehngen.,Mariola Soehngen, wh...
GSK's Cancer Drugs Fast-Tracked for Approval in China
September 13, 2024 11:25 AM BST| By Team Kalkine MediaGSK PLC,(LSE:GSK),has announced that its blood cancer medication, Blenrep (belantamab mafodotin), has been granted Breakthrough Therapy Designation (BTD) in China. This designation, awarded by the National Medical Products Administration (NMPA), is i...
Premier African to Announce Zulu Plant Restart Date Following Lab Tests
September 13, 2024 09:49 AM BST| By Team Kalkine MediaPremier African Minerals Ltd,(LSE:PREM),has received an update from its flotation plant supplier, Enprotec, indicating that no major fundamental changes are required to bring the equipment to optimal performance. Enprotec has been conducting a series...
Futura Medical Consensus Significantly Increases
September 12, 2024 12:23 PM BST| By Team Kalkine MediaAnalysts tracking Futura Medical PLC,(LSE:FUM),have revised and notably increased their revenue forecasts following the company's better-than-anticipated interim results. The sexual healthcare company achieved a maiden profit ahead of schedule, promp...
Haleon Announces Pricing for £1bn Bond Offering
September 12, 2024 11:26 AM BST| By Team Kalkine MediaHaleon PLC,(LSE:HLN),has announced the pricing details for a significant bond offering, expected to raise nearly £1 billion through its subsidiary. The FTSE 100-listed health company revealed that €750 million worth of Euro medium-term notes will be...
